[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640089":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":55,"collaborators":20,"id":57,"slug":20,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Everest Medicines (China) Co.,Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EVER001 200mg bid","EXPERIMENTAL","Participants in this arm receive EVER001 200 mg administered twice daily (bid) orally. This single-arm cohort evaluates the efficacy and safety of EVER001 in subjects with FSGS, MCD, and IgA",[13],"Drug: EVER001",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","EVER001","EVER001 200 mg, oral administration, twice daily (bid), for the treatment of proteinuric glomerular diseases including FSGS , MCD , and IgA",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Fei Liao","CONTACT","+8621- 8012 5712","fei.liao@everestmedicines.com",[28,46],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Peking University First Hospital","RECRUITING","Beijing","Beijing Municipality","100730","China",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":45},"Hong Zhang","+8610-83575530","hongzh@bjmu.edu.cn",{"facility":47,"status":30,"city":48,"state":49,"zip":20,"country":34,"cosmosGeoPoint":20,"geoPoint":20,"contacts":50},"Tianjin Medical University General Hospital","Tianjin","Hebei",[51],{"name":52,"role":24,"phone":53,"phoneExt":20,"email":54},"yan jun Jia","+86-13821735536","jiajunya@126.com",{"type":56,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100640089",false,"NCT07614477","Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases","The Sub-Study 3 of A Phase 1b\u002F2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases (ES108001)","Inclusion Criteria:\n\n* Primary FSGS or MCD\u002FIgAN confirmed by renal biopsy\n* eGFR ≥ 45 mL\u002Fmin\u002F1.73 m²\n* For participants with FSGS or MCD: must have a 24-hour urine protein-to-creatinine ratio (UPCR) \\> 3.5 g\u002Fg and serum albumin \\\u003C 30 g\u002FL during the screening period\n* For participants in the IgAN group: 24-hour UPCR ≥ 0.8 g\u002Fg; ARB or ACEI stable for ≥ 12 weeks prior to Day 1\n* Patients with FSGS or MCD who have not been treated with immunosuppressants or are sensitive to prior immunosuppressant treatment\n\nExclusion Criteria:\n\n* Hereditary or secondary FSGS\u002FMCD; collapsing FSGS\n* BMI ≥ 35 kg\u002Fm² in participants with FSGS\u002FMCD\n* Evidence of diabetes mellitus or a history of diabetes mellitus\n* Acute or chronic infection requiring treatment\n* Patients infected with HIV, hepatitis C, syphilis, or hepatitis B\n* Patients with current or prior inadequately treated active tuberculosis (TB), latent TB, or evidence of current household contact with active TB\n* At risk of bleeding\n* Baseline 24-hour UPCR \\> 3 g\u002Fg and serum albumin \\\u003C 30 g\u002FL in participants with IgAN","ALL","18 Years","75 Years",{"count":67,"type":68},45,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","This is a Phase 1b\u002F2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN. EVER001 acts on multiple immune pathways without directly affecting T cells or depleting B cells (both are lymphocytes). The study will be conducted at \\~30 centers in China, enrolling 45 participants aged 18-75 years (15 per indication). The IMP is a 100 mg oral capsule, dosed at 200 mg twice daily (2 capsules per dose, 4 daily) for 52 weeks.",[74,75,76],"Minimal Change Disease (MCD)","IgA Nephropathy (IgAN)","Focal Segmental Glomerulosclerosis (FSGS)","2026-05-22",{"date":79,"type":80},"2026-05-29","ACTUAL",{"date":82,"type":68},"2026-05-15",{"date":84,"type":68},"2029-03-31",{"name":5,"class":6},2]